Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug

Table 2

Adverse events noted at various drug dosages of CDRI 97/78.

Treatment group	Type of adverse events	No. of events
80 mg CDRI 97/78	Heaviness of head	1
160 mg CDRI 97/78	None
320 mg CDRI 97/78	Visual disturbance	1
400 mg CDRI 97/78	Drowsiness	1
	Bradycardia	1
	Itching	1
500 mg CDRI 97/78	Sedation	1
	Nausea	1
600 and 700 mg CDRI 97/78	Sedation	1
Placebo	Sedation	1
	Drowsiness	1
	Nausea	1
	Retching	1
	Dizziness	1
	Heaviness of head	1